A phase I-II study of bialkylator chemotherapy, high-dose thiotepa, and cyclophosphamide with autologous bone marrow reinfusion in patients with advanced cancer.
- 1 February 1987
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 5 (2) , 260-265
- https://doi.org/10.1200/jco.1987.5.2.260
Abstract
Twenty patients with disseminated cancer both untreated and previously treated received bialkylator chemotherapy, thiotepa, and cyclophosphamide and reinfusion of cryopreserved autologous bone marrow (ABMR). The cyclophosphamide dose was constant at 7.5 g/m2 over three days, while thiotepa was started at 1.8 mg/kg for three days in escalating dose by a modified Fibonacci schema to 7 mg/kg. The median time to recovery of more than 500 granulocytes and more than 50,000 platelets/microL was 18 and 27 days, respectively. Four patients died as a consequence of severe, overwhelming infections or progressive disease during their period of aplasia. Of the 18 evaluable patients, a complete response (CR) was achieved in three patients and a partial response (PR) in ten patients for an overall response rate of 72%. The median duration of response was 14 weeks. Other nonhematologic toxicities included nausea/vomiting, diarrhea, stomatitis, skin rash, and cardiomyopathy. The maximum tolerated dose (MTD) of thiotepa was 700 mg/m2 or 6 mg/kg for three doses. Although there are substantial toxicities associated with this regimen, high-dose thiotepa and cyclophosphamide produce high response rates in patients with disseminated cancer.This publication has 8 references indexed in Scilit:
- Intensive 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU) monochemotherapy and autologous marrow transplantation for malignant glioma.Journal of Clinical Oncology, 1986
- High-dose combination alkylating agents with autologous bone marrow support: a Phase 1 trial.Journal of Clinical Oncology, 1986
- High-Dose Cyclophosphamide, Carmustine, and Etoposide and Autologous Bone Marrow Transplantation for Relapsed Hodgkin's DiseaseAnnals of Internal Medicine, 1986
- Treatment of Resistant Malignant Lymphoma with Cyclophosphamide, Total Body Irradiation, and Transplantation of Cryopreserved Autologous MarrowNew England Journal of Medicine, 1984
- Cyclophosphamide and VP 16-213 with autologous bone marrow transplantation. A dose escalation studyEuropean Journal of Cancer and Clinical Oncology, 1984
- High-dose combination chemotherapy with autologous bone marrow transplantation in adult solid tumorsCancer, 1980
- Cyclophosphamide, Vincristine, Methotrexate with Leucovorin Rescue, and Cytarabine (COMLA) Combination Sequential Chemotherapy for Advanced Diffuse Histiocytic LymphomaAnnals of Internal Medicine, 1980
- Improved survival times in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, vincristine and BCNU: M-2 protocolThe American Journal of Medicine, 1977